1-12 of 12
Peter Wipf
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

(+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist

Ryan N. Cole, Wei Chen, Laura E. Pascal, Joel B. Nelson, Peter Wipf, Zhou Wang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (4): 483–492.
https://doi.org/10.1158/1535-7163.MCT-21-0432
Published: 01 April 2022
View articletitled, (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
Open the PDF for (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist in another window
Includes: Supplementary data
Journal Articles

A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

Zhenyu Yang, Dan Wang, James K. Johnson, Laura E. Pascal, Keita Takubo, Raghunandan Avula, Anish Bhaswanth Chakka, Jianhua Zhou, Wei Chen, Mingming Zhong, Qiong Song, Hui Ding, Zeyu Wu, Uma R. Chandran, Taber S. Maskrey, Joel B. Nelson, Peter Wipf, Zhou Wang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (1): 75–88.
https://doi.org/10.1158/1535-7163.MCT-19-0489
Published: 03 January 2020
View articletitled, A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Open the PDF for A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining In Vivo Antitumor Efficacy

Brian D. Peyser, Ann Hermone, Joseph M. Salamoun, James C. Burnett, Melinda G. Hollingshead, Connor F. McGrath, Rick Gussio, Peter Wipf
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (10): 1765–1774.
https://doi.org/10.1158/1535-7163.MCT-19-0185
Published: 01 October 2019
View articletitled, Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining In Vivo Antitumor Efficacy
Open the PDF for Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining In Vivo Antitumor Efficacy in another window
Includes: Supplementary data
Journal Articles

Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells

Jun Dong, Zeyu Wu, Dan Wang, Laura E. Pascal, Joel B. Nelson, Peter Wipf, Zhou Wang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (1): 39–50.
https://doi.org/10.1158/1535-7163.MCT-18-0432
Published: 02 January 2019
View articletitled, Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Open the PDF for Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Inhibition of Androgen Receptor Nuclear Localization and Castration-Resistant Prostate Tumor Growth by Pyrroloimidazole-based Small Molecules

Khalid Z. Masoodi, Yadong Xu, Javid A. Dar, Kurtis Eisermann, Laura E. Pascal, Erica Parrinello, Junkui Ai, Paul A. Johnston, Joel B. Nelson, Peter Wipf, Zhou Wang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (10): 2120–2129.
https://doi.org/10.1158/1535-7163.MCT-17-0176
Published: 02 October 2017
View articletitled, Inhibition of Androgen Receptor Nuclear Localization and Castration-Resistant Prostate Tumor Growth by Pyrroloimidazole-based Small Molecules
Open the PDF for Inhibition of Androgen Receptor Nuclear Localization and Castration-Resistant Prostate Tumor Growth by Pyrroloimidazole-based Small Molecules in another window
Journal Articles

Protein Kinase D as a Potential Chemotherapeutic Target for Colorectal Cancer

Ning Wei, Edward Chu, Peter Wipf, John C. Schmitz
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (5): 1130–1141.
https://doi.org/10.1158/1535-7163.MCT-13-0880
Published: 05 May 2014
View articletitled, Protein Kinase D as a Potential Chemotherapeutic Target for Colorectal Cancer
Open the PDF for Protein Kinase D as a Potential Chemotherapeutic Target for Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity

Nathan T. Ihle, Robert Lemos, David Schwartz, Junghwan Oh, Robert J. Halter, Peter Wipf, Lynn Kirkpatrick, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (1): 94–100.
https://doi.org/10.1158/1535-7163.MCT-08-0714
Published: 12 January 2009
View articletitled, Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity
Open the PDF for Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity in another window
Journal Articles

A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells

Andreas Vogt, Peter R. McDonald, Aletheia Tamewitz, Rachel P. Sikorski, Peter Wipf, John J. Skoko, III, John S. Lazo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (2): 330–340.
https://doi.org/10.1158/1535-7163.MCT-07-2165
Published: 15 February 2008
View articletitled, A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells
Open the PDF for A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells in another window
Journal Articles

Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase

Garth Powis, Peter Wipf, Stephen M. Lynch, Anne Birmingham, D. Lynn Kirkpatrick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (3): 630–636.
https://doi.org/10.1158/1535-7163.MCT-05-0487
Published: 16 March 2006
View articletitled, Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase
Open the PDF for Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase in another window
Journal Articles

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts

Nathan T. Ihle, Gillian Paine-Murrieta, Margareta I. Berggren, Amanda Baker, Wendy R. Tate, Peter Wipf, Robert T. Abraham, D. Lynn Kirkpatrick, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (9): 1349–1357.
https://doi.org/10.1158/1535-7163.MCT-05-0149
Published: 16 September 2005
View articletitled, The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts
Open the PDF for The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts in another window
Journal Articles

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

Nathan T. Ihle, Ryan Williams, Sherry Chow, Wade Chew, Margareta I. Berggren, Gillian Paine-Murrieta, Daniel J. Minion, Robert J. Halter, Peter Wipf, Robert Abraham, Lynn Kirkpatrick, Garth Powis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (7): 763–772.
https://doi.org/10.1158/1535-7163.763.3.7
Published: 13 July 2004
View articletitled, Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling
Open the PDF for Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling in another window
Journal Articles

The Antisignaling Agent SC-ααδ9, 4-(Benzyl-(2-[(2,5-diphenyloxazole- 4-carbonyl)amino]ethyl)carbamoyl)- 2-decanoylaminobutyric Acid, Is a Structurally Unique Phospholipid Analogue with Phospholipase C Inhibitory Activity

Andreas Vogt, Katharine E. Pestell, Billy W. Day, John S. Lazo, Peter Wipf
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2002) 1 (11): 885–892.
Published: 01 September 2002
View articletitled, The Antisignaling Agent SC-ααδ9, 4-(Benzyl-(2-[(2,5-diphenyloxazole- 4-carbonyl)amino]ethyl)carbamoyl)- 2-decanoylaminobutyric Acid, Is a Structurally Unique Phospholipid Analogue with Phospholipase C Inhibitory Activity
Open the PDF for The Antisignaling Agent SC-ααδ9, 4-(Benzyl-(2-[(2,5-diphenyloxazole- 4-carbonyl)amino]ethyl)carbamoyl)- 2-decanoylaminobutyric Acid, Is a Structurally Unique Phospholipid Analogue with Phospholipase C Inhibitory Activity in another window